Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer

Article

Abstract: Context: Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is ac

Palabras claves:

Autores:

Arlt W., Attard G., Cassidy A.M., De Bono J.S., Dowsett M., Folkerd E., Hughes B.A., Oommen N.B., Reid A.H.M., Richard J. Auchus, Thompson E.

Fuentes:

scopus